MESO

Mesoblast Limited

A maker of "off-the-shelf" cellular medicines, Mesoblast turns adult stem cells from bone marrow into treatments for severe inflammatory conditions, including its therapy Ryoncil for a life-threatening complication of bone-marrow transplants. Founded in Melbourne in 2004 by Dr. Silviu Itescu, its name blends "mesenchyme" (its cell type) with "-blast," a biological term for a developing cell. In late 2024 Ryoncil became the first stem-cell therapy of its kind to win US approval.

American Depositary Receipts

No proxy statement recorded.